【摘要】 目的：比较^８９Ｓｒ和^１５３Ｓｍｉｎ－ＥＤＴＭＰ治疗鼻咽癌（ｎａｓｏｐｈａｒｙｎｇｅａｌ ｃａｒｃｉｎｏｍａ， ＮＰＣ）多发性骨转移瘤的疗效。方法：从１９９７年５月到１９９９年３月，作者用^８９Ｓｒ和^１５３Ｓｍ－ＥＤＴＭＰ分别治疗ＮＰＣ多发性骨转移瘤病人４５例和６８例。根据治疗前后骨痛缓解和生活质量的情况决定疗效，同时比较其病灶摄取放射性变化，观察开始起效的时间，对病人血清ＶＣＡ－ＩｇＡ、ＥＡ－ＩｇＡ水平和骨髓造血功能的影响。结果：^８９Ｓｒ和^１５３Ｓｍ－ＥＤＴＭＰ治疗ＮＰＣ多发性骨转移瘤的有效率分别为 ８６． ７％和 ８８.２％，治疗后起效的时间为 １１.０和 ７.２天；治疗前后和两组骨转移灶 ＲＯＩ值变化、对 ＮＰＣ病人血清 ＶＣＡ－ＩｇＡ、ＥＡ－ＩｇＡ水平和外周血相的影响有显著性差别（ Ｐ＜ ０．０５）。结论：^８９Ｓｒ和¹⁵³Ｓｍ－ＥＤＴＭＰ对 ＮＰＣ骨转移病人的疼痛缓解和生活质量的提高有肯定疗效。^１５３Ｓｍ－ＥＤＴＭＰ对ＮＰＣ骨转移灶的抑制作用明显强于^８９Ｓｒ，可以部分降低ＶＣＡ－ＩｇＡ和ＥＡ－ＩｇＡ水平。～（１５３）Ｓｍ－ＥＤＴＭＰ的骨髓毒性较^８９Ｓｒ严重。更多还原

【Abstract】 Objective: To compare treatment result of ⁸⁹Sr and ¹⁵³Sm-EDTMP in nasopharyngeal carcinoma （NPC） patients with bone metastases. Methods: NPC patients with bone metastases were treated using ⁸⁹Sr （45 cases） or ¹⁵³Sm-EDTMP （68 cases）. The effectiveness was determined by pain relief and life quality improvement, changes of bone morrow function and VCA-IgA, EA-IgA level. Results: The response rate to ⁸⁹Sr and ¹⁵³Sm-EDTMP was 86.7% and 88.2%. respectively （P>0.05）. The effective period following treatment was 11.0 and 7.2 days, and bone morrow repression rate was 22% and 42%, respectively. These differences were significant （P<0.02）. The influence to serum VCA-IgA and EA-IgA level, and radioactive uptake of bone lesion ROI following ⁸⁹Sr or ¹⁵³Sm-EDTMP treated was significantly different （P <0.05）. Conclusions: ⁸⁹Sr and ¹⁵³Sm-EDTMP can relief bone pain and improve patient’s life quality. ¹⁵³Sm-EDTMP may repress bone metastases stronger than ⁸⁹Sr, and can decrease patient’s serum VCA-IgA and EA-IgA level, but the blood toxity is also more serious than ⁸⁹Sr.更多还原